EXEL - Exelixis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.24
-0.02 (-0.10%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.26
Open19.23
Bid19.23 x 29200
Ask19.24 x 1200
Day's Range18.88 - 19.54
52 Week Range13.42 - 25.31
Volume2,245,766
Avg. Volume2,611,614
Market Cap5.828B
Beta (3Y Monthly)1.69
PE Ratio (TTM)9.40
EPS (TTM)2.05
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.45
Trade prices are not sourced from all markets
  • Renal Cell Carcinoma Space in Focus: Some Key Developments
    Zacks

    Renal Cell Carcinoma Space in Focus: Some Key Developments

    The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.

  • Biotech vet George Scangos steers new company toward nine-figure IPO
    American City Business Journals

    Biotech vet George Scangos steers new company toward nine-figure IPO

    The CEO who built Exelixis and reshaped Biogen now wants to lead a nine-figure IPO for San Francisco's Vir Bio.

  • These Fundamentals Make Exelixis, Inc. (NASDAQ:EXEL) Truly Worth Looking At
    Simply Wall St.

    These Fundamentals Make Exelixis, Inc. (NASDAQ:EXEL) Truly Worth Looking At

    Exelixis, Inc. (NASDAQ:EXEL) is a stock with outstanding fundamental characteristics. When we build an investment...

  • 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar
    InvestorPlace

    10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar

    [Editor's note: "10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar" was previously published in July 2019. It has since been updated to include the most relevant information available.]2019 has been a seemingly good year for the broad market, but take a closer look. That strength has been limited to large caps. In the last three months, the S&P 500 has gained 2.4%, while the Russell 2000 small cap index has given up 1.4% of its value. The S&P 600 small cap index, with an even smaller typical market cap, is down nearly 4% in the last month.The group-wide weakness of the recent past, however, doesn't necessarily portend more weakness for all of these names in the foreseeable future. Indeed, as investors seek to lock in profits on their more recognizable large-cap positions, it's small-cap stocks that are most likely to be viewed as oversold, undervalued opportunities.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Marijuana Stocks to Ride High on the Farm Bill With that as the backdrop, here's a rundown of ten up-and-coming stocks that could energize portfolios at a time when more familiar names have little left to give. Not all of these names will ring a bell. But, that's the point. Bunge (BG)Source: Shutterstock Odds are good you've eaten something within the past 24 hours that Bunge (NYSE:BG) helped put on your plate. The company is one of the biggest global suppliers of grains like corn and wheat, but it also sells fertilizers, milled products and edible oils like olive oil and coconut oil.It isn't stopping there though. At the same time it's addressing the world's food scarcity crisis by establishing facilities closer to where needs exist, Bunge is also taking aim at the burgeoning energy crises. It and oil giant BP (NYSE:BP) announced this week they'll be working on a bioenergy project that makes the pair the world's third-biggest sugarcane processor.It's all working. Though revenue growth has been and will remain modest, these are businesses that scale well. This year's expected per-share earnings of $3.65 are projected to reach $3.84 next year. Exelixis (EXEL)Source: Shutterstock Exelixis (NASDAQ:EXEL) is a small biopharma outfit primarily focused on the treatment of cancer. Its flagship product, Cabometyx, accounts for roughly 80% of the EXEL's business, while collaboration income makes up most of the remainder.Exelixis isn't stopping with the development of Cabometyx's underlying tyrosine kinase-inhibitor though. The same molecular formula is now the basis of several dozen different clinical trials -- including a couple of phase three tests -- most of which are being handled by other pharmaceutical companies that want to use Exelixis' cabozantinib in conjunction with another drug. * 10 Marijuana Stocks to Ride High on the Farm Bill It's not a recipe for a massive, one-off growth spurt. But EXEL has set the stage for years of potential double-digit sales and earnings growth. Teladoc Health (TDOC)Source: Shutterstock Teladoc Health (NYSE:TDOC) isn't a profitable company, but at its current pace of progress, there's a light at the end of the tunnel. This year's and enxt year's top line are expected to improve by nearly 25%. That improvement should shrink 2020's loss meaningfully.It's a business model whose time has not only come, but is a sign of the times. Teladoc Health, in simplest terms, let's patients receive medical attention online. Rather than having to go into a doctor's office, an internet-based conversation -- either video chatting or a voice call -- can get you the clinical medical attention you need. Teladoc's doctors can even write a prescription when necessary. Brooks Automation (BRKS)Source: Shutterstock It was inevitable. As improved computers in turn improved robotics, manufacturing organizations would increasingly automate their operations. Not only are robots cheaper than humans, they tend to fabricate more precise products.Enter Brooks Automation (NASDAQ:BRKS), which offers automation solutions manufactures want, and even need.The company has carved out a couple of niches in the most lucrative of industries. That is, Brooks caters specifically to semiconductor makers, and life sciences companies. Its Spartan Sorters, for instance, handle ultra-thin wafers used in high-end technologies, allowing the fabrication of electronics components in a perfectly dust-free environment that might otherwise compromise the functioning of that component. * 10 Marijuana Stocks to Ride High on the Farm Bill In the red just three years ago, Brooks has found a bullish (and profitable) groove, easily qualifying BRKS as one of the top up-and-coming stocks among small-cap names. Qorvo (QRVO)Source: Shutterstock Speaking of semiconductor technologies, add Qorvo (NASDAQ:QRVO) to the list of small cap stocks to mull. Whereas Brooks Automation makes a means of handling them, Qorvo makes the chips that need special care when handling.It's clearly not an Intel (NASDAQ:INTC). It's not even a Texas Instruments (NASDAQ:TXN). Don't let its small size fool you though. What Qorvo may not be a head turner, but it's got a diverse menu of technology products that serve industries ranging from automobiles to mobile devices to aerospace outfits to the nascent Internet of Things arena.The advent of 5G connections (and the subsequent Internet of Things era it will help usher in) appears to be a particularly strong opportunity for the company. Not only does Qorvo make some of the 5G components used in 5G handsets, it makes solutions for so-called 'smart homes' that will be monitored and managed using those ultra-high-speed connections. Graphic Packaging Holding Company (GPK)You don't likely know it, but it would be unusual if within the past week you hadn't seen, or even touched, something made by Graphic Packaging Holding Company (NYSE:GPK). The company makes a variety of packaging solutions, particularly for the food and beverage industries, but also manufactures cartons that can double as display solutions.It's hardly a riveting business, but it's one that lends itself to scaling up. And, Graphic Packaging has kept things interesting by doing just that. GPK shares jumped more than 7% on Tuesday in response to the company's second quarter earnings beat that was at least partially driven by last year's acquisition of PFP and part of Letica Foodservice, and partially driven by its relatively new status as an approved member of Amazon's Packaging Support and Supplier Network. * 10 Marijuana Stocks to Ride High on the Farm Bill The company also announced ts intention to buy Artistic Carton, setting up more scale for later this year and beyond. Arrow Electronics (ARW)Source: Shutterstock Add Arrow Electronics (NYSE:ARW) to your list of noteworthy up-and-coming stocks. Though this year is proving to be a tough one that's taken a toll on the stock's price, the company is expected to start growing in earnest again come next year.If you need an electronics component, or even a completely self-contained system on a circuit board, Arrow Electronics probably offers it. If not, it can find or even develop one. The company sells thousands of various amplifiers, converters, capacitors, sensors, switches and more. None of it is sexy, but all of it is marketable.And the tech industry has taken notice. Microsoft (NASDAQ:MSFT) recently deemed Arrow Electronics to be one of the technology sector's top providers of Microsoft-based solutions for 2019. Catalent (CTLT)Source: Shutterstock If you've ever wondered who makes the capsules and coatings that surround pills and then melt in your stomach, it's rarely the drug's actual manufacturer. A company called Catalent (NYSE:CTLT) supplies them.That's only a fraction of the drug-delivery solutions the company brings to the table though. Catalent also offers spray-drying technology to improve a medicine's solubility, beauty-related packaging and drug-development solutions just to name a few more. Its lineup largely consists of the things consumers take for granted, but couldn't live without.It's not a high-growth business. It's a company that saw explosive growth in 2017, though, that's still largely being overlooked. * 10 Marijuana Stocks to Ride High on the Farm Bill And that's a big mistake. Patient investors would have been rewarded with a 79% gain thus far in 2019. And, with its growing role in the field of gene therapies, similar upside may still be on the table. F.N.B. Corp (FNB)Source: Shutterstock It's certainly no threat to the likes of Bank of America (NYSE:BAC) or Wells Fargo (NYSE:WFC)… at least not yet. Regional bank F.N.B. Corp (NYSE:FNB) is still a name to respect though, and perhaps even invest in.F.N.B. Corp -- consumers in the northeastern part of the country know it better as First National Bank -- operates nearly 400 branches in seven different states, sporting an asset base in excess of $30 billion. That leaves the bank in something of a sweet spot, where it's got enough size to make use of its fiscal muscle, but isn't so big that it's crimped by the Fed's banking rules specifically taking aim at institutions that are 'too big to fail.'More important, F.N.B. is a steady-growth machine. Through a combination of acquisitions and smart execution, the company hasn't failed to grow operating income in any quarter since 2011. XPO Logistics (XPO)Source: Shutterstock One wouldn't think a logistics market that already included the likes of United Parcel Service (NYSE:UPS) and FedEx (NYSE:FDX) would even allow another player to take shape, let alone thrive.But XPO Logistics (NYSE:XPO) is doing something most enterprising newcomers to any market try to do. They're using their competition's sheer size against them, and leveraging technology to become a highly-nimble service provider for organizations that need very specific solutions. XPO is more of a supply chain consultant than a shipping company. It identifying where inefficiencies exist -- something FedEx and UPS haven't quite embraced.The company's results underscore the argument that XPO is one of a handful of up-and-coming stocks worth a closer look. Though revenue has only been growing at a single-digit pace, per-share earnings are expected to reach $3.86 this year, up from last year's $3.19, and then soar to $4.65 in 2020.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post 10 Small-Cap, Up-And-Coming Stocks to Keep on Your Radar appeared first on InvestorPlace.

  • GuruFocus.com

    Exelixis Inc (EXEL) EVP and General Counsel Jeffrey Hessekiel Sold $1.6 million of Shares

    EVP and General Counsel of Exelixis Inc (30-Year Financial, Insider Trades) Jeffrey Hessekiel (insider trades) sold 75,000 shares of EXEL on 08/16/2019 at an average price of $21.1 a share. Continue reading...

  • Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales
    Zacks

    Exelixis (EXEL) Stock Up 15.2% YTD on Strong Cabometyx Sales

    Exelixis (EXEL) continues to fortify its footing in the kidney cancer market on strong Cabometyx performance.

  • GuruFocus.com

    Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $704,654 of Shares

    President and CEO of Exelixis Inc (30-Year Financial, Insider Trades) Michael Morrissey (insider trades) sold 35,040 shares of EXEL on 08/14/2019 at an average price of $20.11 a share. Continue reading...

  • Thomson Reuters StreetEvents

    Edited Transcript of EXEL earnings conference call or presentation 31-Jul-19 9:00pm GMT

    Q2 2019 Exelixis Inc Earnings Call

  • Exelixis Hits Blockbuster Status
    Motley Fool

    Exelixis Hits Blockbuster Status

    The biotech needed help from some friends to get there.

  • Is Exelixis, Inc. (NASDAQ:EXEL) A High Quality Stock To Own?
    Simply Wall St.

    Is Exelixis, Inc. (NASDAQ:EXEL) A High Quality Stock To Own?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

  • GuruFocus.com

    Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $709,560 of Shares

    President and CEO of Exelixis Inc (30-Year Financial, Insider Trades) Michael Morrissey (insider trades) sold 35,040 shares of EXEL on 08/02/2019 at an average price of $20.25 a share. Continue reading...

  • Exelixis Stock Rises on Revenue Beat
    Market Realist

    Exelixis Stock Rises on Revenue Beat

    Yesterday, Exelixis (EXEL) reported its second-quarter results after markets closed. Subsequently, its stock rose 0.99% and closed at $21.48.

  • Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines
    Zacks

    Exelixis (EXEL) Q2 Earnings & Sales Beat, Cabometyx Shines

    Exelixis (EXEL) beats on earnings and sales in the second quarter, as lead drug Cabometyx continues momentum.

  • Benzinga

    The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 1) Grifols SA - ADR ADR Class B (NASDAQ: GRFS ) Odonate ...

  • Exelixis Inc (EXEL) Q2 2019 Earnings Call Transcript
    Motley Fool

    Exelixis Inc (EXEL) Q2 2019 Earnings Call Transcript

    EXEL earnings call for the period ending June 30, 2019.

  • Exelixis (EXEL) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Exelixis (EXEL) Q2 Earnings and Revenues Beat Estimates

    Exelixis (EXEL) delivered earnings and revenue surprises of 8.70% and 5.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals ...

  • Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?
    Zacks

    Exelixis (EXEL) to Report Q2 Earnings: What's in the Cards?

    Exelixis' (EXEL) second-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.

  • 3 Cancer Treatment Stocks to Buy Right Now
    Motley Fool

    3 Cancer Treatment Stocks to Buy Right Now

    These three businesses are poised to profit from the war on cancer.

  • Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
    Zacks

    Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?
    Zacks

    Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?

    Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • GuruFocus.com

    Exelixis Inc (EXEL) President and CEO Michael Morrissey Sold $741,988 of Shares

    President and CEO of Exelixis Inc (30-Year Financial, Insider Trades) Michael Morrissey (insider trades) sold 34,721 shares of EXEL on 07/17/2019 at an average price of $21.37 a share. Continue reading...